Filing Flows › Adma Biologics (ADMA) › Stock forecast & fair value
Adma Biologics (ADMA) stock forecast and price target
Adma Biologics (ADMA) trades at $12.73. 4 analysts' median price target is $17.50 (+37%), from $12.00 to $21.00.
Adma Biologics' latest quarter
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for ADMA stock?
The median of 4 analysts' 12-month targets is $17.50, +37% from $12.73; the range is $12.00 to $21.00. The average rating is none.
Does Adma Biologics usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is ADMA stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.